TWO ARTICLES IN THIS ISSUE of the American Journal of Physiology-Regulatory, Integrative and Comparative
Physiology address the importance of angiotensin hormone "fragments." Before focusing on the angiotensin "fragments," the main functions of the renin-angiotensin system (RAS) are briefly outlined.
The control of total body sodium and water by the kidney has a pivotal role in the long-term control of mean arterial blood pressure (MAP; 4, 10) . Whereas the function of the arterial baroreceptor reflex seems to be limited to the sensing and the correction of rapid short-term pressure changes around long-term MAP (5, 16) , the cardiopulmonary receptors in the low-pressure system provide important information on the degree of vascular filling (16) . It seems unlikely that by using the latter afferents the central nervous system (CNS) can detect changes in total body sodium or water, a prerequisite for the necessary long-term correcting adjustments. However, there are two fundamental mechanisms, serving as input and output, which are driven directly by MAP via renal perfusion pressure: 1) the acute pressure-natriuresis mechanism affecting sodium and water excretion and 2) pressuredependent renin release, which functionally characterizes the strongest stimulus for renin synthesis (18) and release (9, 11) . However, both mechanisms are modulated effectively by neural, hormonal, and intrarenal paracrine and endocrine influences (4, 7, 12) ; therefore the kidney actually integrates many different inputs. By providing circulating ANG II, which acts on the CNS via the circumventricular organs, the kidney even determines the set point of the neural control mechanisms. There is evidence that a chronic infusion of ANG II (1, 2) or a 2-h servo-controlled fall of renal perfusion pressure (for literature, see Ref. 11) resets the arterial baroreceptor reflex toward a higher level of MAP. A chronic infusion of ANG II can also attenuate the renal sympathoinhibitory response to acute volume expansion, an effect that is probably mediated by AT 1 receptors (13) .
Previous studies on the regulatory actions of the RAS focused overwhelmingly on ANG II. But other studies, mostly published in the last decade, have suggested that the so-called fragments of ANG II may, in fact, serve as biologically active hormones (3, 8) . 1-8) by the ACE-related enzyme ACE 2 (6, 21) . As endopeptidases are present in epithelial, neuroepithelial, endothelial, and smooth muscle cells, this peptide might have mainly an autocrine/paracrine role. In humans, the plasma concentrations of ANG-(1-7) are lower than those of ANG II-(1-8) and ANG III-(2-8) [1:14 and 1:3, respectively (14)]. Because the effects of ANG-(1-7) can be abolished by high doses of AT 1 antagonists, they might be mediated in part by AT 1 receptors. Whether high-affinity binding sites different from AT 1 receptors characterize a specific receptor different from AT 1 remains controversial (3). The major effect of ANG-(1-7) in the CNS is vasopressin release. The mechanisms of the cardiovascular vasodilatory effects of ANG-(1-7) are complex and may, de-pending on the vascular bed, rely on a receptor-mediated facilitation of NO or prostaglandin release. It also was suggested (8) that this peptide has a counterbalancing effect to ANG II- (1) (2) (3) (4) (5) (6) (7) (8) . The renal effects of ANG-(1-7) were recently reviewed in detail (19) . Briefly, ANG-(1-7) locally interacts with the bradykinin-kinin system. There also may exist an interaction between ANG-(1-7) and ANG II-(1-8) at the renal level, but it is poorly understood. The primary route of degradation of ANG-(1-7) is via ACE (for literature, see Ref. 8) .
In companion papers in this issue (17, 22) , the cardiovascular, endocrine, and renal effects of ANG III-(2-8), ANG IV-(3-8), and ANG-(1-7) are compared with those of ANG II-(1-8) under physiological conditions in conscious dogs and in humans. The angiotensins were applied in equimolar physiological concentrations while the RAS was acutely blocked by converting enzyme inhibition, and the effects of endogenously formed aldosterone were prevented by an aldosterone antagonist. Because most of the previous investigations on the biological effects of the angiotensin fragments either were in vitro studies or were made in anesthetized animals, these two publications make an important contribution to the integrative physiology of angiotensins. However, there are still many open questions. Further research in this area will hopefully tell us soon which of these fragments we may call biologically active hormones.
